HIV–1 resistance to dolutegravir: update and new insights

Integrase strand transfer inhibitors (INSTIs) are the latest class of potent anti-HIV drugs. Currently, three INSTIs have been approved by the US Food and Drug Administration: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). Resistance mutations to RAL and EVG emerge rapidly, and signif...

Descripción completa

Detalles Bibliográficos
Autores principales: Wainberg, Mark A, Han, Ying–Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2015
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946665/
https://www.ncbi.nlm.nih.gov/pubmed/27482391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946665/
https://www.ncbi.nlm.nih.gov/pubmed/27482391

Ejemplares similares